Sign in Subscribe
United States. Securities and Exchange Commission

Amgen Inc. Submits SEC Filing Reporting Material Corporate Changes

Strategic Insights

— 1 min read

Amgen Inc., a leading biopharmaceutical company, recently submitted a Form 8-K SEC filing to report material corporate changes. The filing, made on August 4, 2022, indicates that the company has experienced significant events or corporate changes that are of importance to investors or security holders. As a publicly-traded company, Amgen Inc. is required to submit regular financial statements and report on significant corporate events to the U.S. Securities and Exchange Commission (SEC). The company's filing provides more current information on these events than its annual or quarterly reports, giving investors and stakeholders a clearer understanding of the company's financial situation and growth prospects.

Key Takeaways:

  • Amgen Inc. submitted a Form 8-K SEC filing on August 4, 2022, to report material corporate changes.
  • The filing indicates that the company has experienced significant events or corporate changes important to investors or security holders.
  • The company's SIC code is 2836, Biological Products, (No Diagnostic Substances).
  • The SEC filing includes 16 documents, with the SEC file number being 0000318154-22-000039.
  • The contact information for Amgen Inc. can be found at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320, with a phone number of (805)447-1000.
  • Form 8-K provides more current information on specified events than Forms 10-Q or 10-K.
  • The filing is a formal document submitted to the SEC by publicly-traded companies, such as Amgen Inc.
  • Amgen Inc. operates in the biopharmaceutical industry, producing biologics and other pharmaceutical products.

Statistics:

  • The filing was submitted on August 4, 2022 (date of SEC filing).
  • Amgen Inc. operates in Standard Industrial Classification (SIC) code 2836, Biological Products.
  • The company has 16 documents filed with the Form 8-K filing.
  • The SEC file number for the filing is 0000318154-22-000039.
  • The contact information for Amgen Inc. includes a physical address: ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320.
  • The company's phone number is (805)447-1000.

Sources:

  • News Release. (2022, August 24). Amgen Inc. Submits SEC Filing Reporting Material Corporate Changes. Retrieved from https://www.sec.gov/Archives/edgar/data/318154/0000318154-22-000039-index.html
  • NewsRx Staff. (2022, August 24). NewsRx - Biotech Week. Retrieved from https://www.newsrx.com/news/2022/08/24/Amgen-Inc-Submits-SEC-Filing-Reporting-Material-Corporate-Changes-3996926.html

Read more